References
1. Levine HL. Presentation at Cambridge Healthcare Institute 8th Annual PepTalk Conference; 2009 Jan; San Diego, CA.
2. Kenneth TE, Kertes PJ Ranibizumab in neovascular age-related macular degeneration. Clin Interv Aging. 2006;1:451–66.
3. Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN Certolizumab pegol. A monthly subcutaneously administered
Fc-free ant-TNF alpha, improves health related quality of life in patients with moderate to severe Crohn's disease. Int J
Colorectal Dis. 2008;23:289–96.
4. Padlan EA. Anatomy of the antibody molecule. Mol Immunol. 1994;31169–217.
5. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126–36.
6. Better M, Chang CP, Robinson RR, Horwitz AH. Escherichia coli secretion of an active chimeric antibody fragment. Science.
1988; 240:1041–43.
7. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science. 1988;240:1038–41.
8. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable
domains secreted from Escherichia coli. Nature. 1989;341:544–46.
9. Woolven BP, Frenken L, van der Logt P, Nicholls PJ. The structure of the llama heavy chain constant genes reveals a mechanism
for heavy-chain antibody formation. Immunogenetics. 1999;50:98–101.
10. Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ, Nuttall SD. Structural evidence for evolution of shark
Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci USA. 2004;101:12444–49.
11. Jespers L, Schon, O, James LC, Vesprintsev, D, Winter G. Crystal structure of HEL4, a soluble, refoldable human VH single
domain with a germ-line scaffold. J Mol Biol. 2004;337:893–903.
12. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal
antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–1800.
13. Casey JL, Napier MP, King DJ, Pedley RB, Chaplin LC, Weir N, et al. Tumour targeting of humanised cross-linked divalent-Fab'
antibody fragments: a clinical phase I/II study. Br J Cancer. 2002;86:1401–10.
14. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody
inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12:6144–152.
15. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol. 2008;20:479–85.
16. Arbabi-Ghahroudi M, Tanha J, MacKenzie R Prokaryotic expression of antibodies. Cancer Metastasis Rev. 2005;24:501–19.
17. Nyyssönen E, Penttila M, Harkki A, Saloheimo A, Knowles JK, Keranen S. Efficient production of antibody fragments by
the filamentous fungus Trichoderma reesei. Biotechnol (NY). 1993;11:591–95.
18. Freyre FM, Vazquez JE, Ayala M, Canaan-Haden L, Bell H, Rodriguez I, et al. Very high expression of an anti-carcinoembryonic
antigen single chain Fv antibody fragment in the yeast Pichia pastoris. J Biotechnol. 2000;6:157–63.
19. Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh AA. Over expression of anti-MUC1 single-domain antibody fragments in
the yeast Pichia pastoris. Mol Immunol. 2006;43:426–35.
20. Harmsen MM, Van Solt CB, Fijten HPD, Van Setten MC. Prolonged in vivo residence times of llama single-domain antibody
fragments in pigs by binding to porcine immunoglobulins. Vaccine. 2005; 23:4926–934.
21. Frenken LGJ, van der Linden RH, Hermans PW, Bos JW, Ruuls RC, de Geus B, Verrips CT. Isolation of antigen specific llama
VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. 2000;78:11–21.
22. Humphreys DP, Heywood SP, Henry A, Ait-Lhadj L, Antoniw P, Palframan R, et al. Alternative antibody Fab' fragment PEGylation
strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.
Protein Eng Des Sel. 2007;20:227–34.
23. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54:531–45.
24. Shaunak S, Godwin A, Choi JW, Balan S, Pedone E, Vijayarangam D, et al. Site-specific PEGylation of native disulfide
bonds in therapeutic proteins. Nat Chem Biol. 2006;2:312–13.
25. Brocchini S, Godwin A, Balan S, Choi JW, Zloh M, Shaunak S. Disulfide bridge based PEGylation of proteins. Adv Drug Deliv
Rev. 2008;60:3–12.
|
